Bendamustine for Lymphoma & Leukemia: Side Effects & Dosage

//Bendamustine for Lymphoma & Leukemia: Side Effects & Dosage

Bendamustine for Lymphoma & Leukemia: Side Effects & Dosage

Bendamustine for Lymphoma & Leukemia: Side Effects & Dosage [the_ad id=”28610″]

Generic drug: bendamustine hydrochloride

Brand name: Treanda

What is Treanda (bendamustine hydrochloride), and how does it work?

Treanda (bendamustine hydrochloride) injection is an antineoplastic (anticancer) medication used to treat chronic lymphocytic leukemia. Treanda is also used to treat indolent B-cell non-Hodgkin lymphoma after other medications have been tried without successful treatment of this condition.

What are the side effects of Treanda?

Common side effects of Treanda include:

What is the dosage for Treanda?

Selection Of Treanda Formulation To Administer

Dosing Instructions For CLL

Recommended Dosage

The recommended dose is 100 mg/m² administered intravenously over 30 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles.

Dose Delays, Dose Modifications And Reinitiation Of Therapy For CLL
  • Delay Treanda administration in the event of Grade 4 hematologic toxicity or clinically significant ≥ Grade 2 nonhematologic toxicity. Once non-hematologic toxicity has recovered to less than or equal to Grade 1 and/or the blood counts have improved [Absolute Neutrophil Count (ANC) ≥ 1 x 109/L, platelets ≥ 75 x 109/L],
    reinitiate Treanda at the discretion of the treating physician. In addition,
    consider dose reduction.
  • Dose modifications for hematologic toxicity: for Grade 3 or greater toxicity, reduce the dose to 50 mg/m² on Days 1 and 2 of each cycle; if Grade 3 or greater toxicity recurs, reduce the dose to 25 mg/m² on Days 1 and 2 of each cycle.
  • Dose modifications for non-hematologic toxicity: for clinically significant Grade 3 or greater toxicity, reduce the dose to 50 mg/m² on Days 1 and 2 of each cycle.
  • Consider dose re-escalation in subsequent cycles at the discretion of the treating physician.

Dosing Instructions For NHL

Recommended Dosage

The recommended dose is 120 mg/m² administered intravenously over 60 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles.

Dose Delays, Dose Modifications And Reinitiation Of Therapy For NHL
  • Delay Treanda administration in the event of a Grade 4 hematologic toxicity or clinically significant greater than or equal to Grade 2 non-hematologic toxicity. Once non-hematologic toxicity has recovered to ≤ Grade 1 and/or the blood counts have improved [Absolute Neutrophil Count (ANC) ≥ 1 x 109/L, platelets ≥ 75 x 109/L],
    reinitiate Treanda at the discretion of the treating physician. In addition,
    consider dose reduction.
  • Dose modifications for hematologic toxicity: for Grade 4 toxicity, reduce the dose to 90 mg/m² on Days 1 and 2 of each cycle; if Grade 4 toxicity recurs, reduce the dose to 60 mg/m² on Days 1 and 2 of each cycle.
  • Dose modifications for non-hematologic toxicity: for Grade 3 or greater toxicity, reduce the dose to 90 mg/m² on Days 1 and 2 of each cycle; if Grade 3 or greater toxicity recurs, reduce the dose to 60 mg/m² on Days 1 and 2 of each cycle.




SLIDESHOW


Signs of Cancer in Men: Could it Be Cancer?
See Slideshow

What drugs interact with Treanda?

Effect Of Other Drugs On Treanda

CYP1A2 Inhibitors
  • The coadministration of Treanda with CYP1A2 inhibitors may increase
    bendamustine plasma concentrations and may result in increased incidence of
    adverse reactions with Treanda.
  • Consider alternative therapies that are not CYP1A2 inhibitors during treatment with
    Treanda.
CYP1A2 Inducers
  • The coadministration of Treanda with CYP1A2 inducers may decrease
    bendamustine plasma concentrations and may result in decreased efficacy of
    Treanda.
  • Consider alternative therapies that are not CYP1A2 inducers during treatment with
    Treanda.

Is Treanda safe to use while pregnant or breastfeeding?

  • Advise pregnant women and females of reproductive potential of the potential risk to a fetus.
  • Advise females to inform their healthcare provider of a known or suspected pregnancy.
  • Advise female patients of reproductive potential to use effective contraception during treatment with
    Treanda and for at least 6 months after the final dose.
  • Males with female partners of reproductive potential should use effective contraception during treatment with
    Treanda and for at least 3 months after the final dose.
  • Females should not breastfeed during treatment with Treanda and for at least 1 week after the final dose.

Medically Reviewed on 3/19/2021

References


All sections courtesy of the U.S. Food and Drug Administration

[the_ad id=”28610″]
2021-11-02T12:32:29+08:00 March 21st, 2021|Categories: Disease & Treatment|Tags: |0 Comments

Leave a Reply